Comparison of Her-2, EGFR and Cyclin D1 in Primary Breast Cancer and Paired Metastatic Lymph Nodes: An Immunohistochemical and Chromogenic In Situ Hybridization Study.
10.3346/jkms.2008.23.6.1053
- Author:
Eun Yoon CHO
1
;
Jae Joon HAN
;
Yoon La CHOI
;
Kyoung Mee KIM
;
Young Lyun OH
Author Information
1. Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. bijou@skku.edu
- Publication Type:Original Article
- Keywords:
CISH;
Her-2;
EGFR;
Cyclin D1;
Immunohistochemistry
- MeSH:
Adult;
Aged;
Breast Neoplasms/genetics/*metabolism/pathology;
Chromogenic Compounds;
Cyclin D1/*analysis/genetics;
Female;
Humans;
Immunohistochemistry;
In Situ Hybridization;
Lymph Nodes/*metabolism/pathology;
Lymphatic Metastasis;
Male;
Middle Aged;
Neoplasm Recurrence, Local/genetics/metabolism;
Receptor, Epidermal Growth Factor/*analysis/genetics;
Receptor, erbB-2/*analysis/genetics;
Survival Analysis
- From:Journal of Korean Medical Science
2008;23(6):1053-1061
- CountryRepublic of Korea
- Language:English
-
Abstract:
The significant advance in the development of molecular-targeting drugs has made an evaluation of Her-2, EGFR, and cyclin D1 an important clinical issue in breast cancer patients. This study compared the Her-2, EGFR, and cyclin D1 status of primary tumors as well as their matching lymph node metastases using immunohistochemistry (IHC) and chromogenic in situ hybridization (CISH) in 73 breast cancer patients. Her-2, EGFR, and cyclin D1 protein showed a concordance between the primary lesion and the metastatic regional lymph nodes in 82%, 90%, and 63%, respectively. CISH also revealed 92%, 93%, and 85% concordance in the gene amplification status of Her-2, EGFR, and cyclin D1, showing a reasonable agreement between primary tumors and metastatic regional lymph nodes. Although a statistically significant agreement was found in Her-2 expression, a relatively high discordance rate (18%) raises a little concern. Our findings suggest that the Her-2 status can be reliably assessed on primary tumor but a possible difference can be found in Her-2, EGFR, and cyclin D1 status between the primary and the metastatic sites and this possibility should be concerned in patients considering molecular targeted therapy or patients with progress of disease.
